A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers

Inclusion Criteria: * Patients must have histologically documented invasive epithelial ovarian, extraovarian, fallopian tube or endometrial carcinoma. * Patients must have persistent or recurrent disease after standard debulking/staging surgery and conventional therapy. * Patients must have evidence of intraabdominal disease; disease may be measurable or nonmeasurable. * Patients must have a GOG performance status of 0, 1, or 2, and have a life expectancy of greater than 3 months. * Patients must have adequate hematologic, renal, and hepatic function defined as: * WBC \> 3,000 ul * Granulocytes \> 1,500 ul * Platelets \> 100,000 * Creatinine clearance \> 80 mg/dl or serum creatinine \> 2.0 * Serum transaminases \< 2.5 x upper limits of normal * Normal serum bilirubin * PT/PTT/INR \< 1.5 x institutional ULN * O2 saturation \> or = 92 % * Patients must be 19 years or older and must have signed informed consent Exclusion Criteria: * Patients with epithelial tumors of low malignant potential, stromal tumors and germ cell tumors of the ovary are ineligible to participate in the study. * Patients with the only site of disease located beyond the abdominal cavity are ineligible to participate in the study. * Patients who are pregnant or lactating are ineligible to participate in the study. * Patients with a GOG performance status of 3 or 4 are ineligible to participate in the study. * Patients with active heart disease (characterized by angina, unstable arrhythmia, congestive heart failure or EF \< 55%, pulmonary hyper- tension, active or chronic debilitating pulmonary disease(i.e., active pneumonia, severe COPD, pulmonary edema, O2 saturation \< 92%), or coagulation disorders (i.e. bleeding disorders, or on therapeutic anti- coagulants)